Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 16Colorectal Neoplasms 7Small Cell Lung Carcinoma 4Neoplasm Metastasis 4Stomach Neoplasms 3Recurrence 3Biliary Tract Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Triple Negative Breast Neoplasms 1Somatostatinoma 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Rectal Neoplasms 1Rectal Cancer Patients 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic to Liver 1Pancreatic Adenocarcinoma 1PDAC - Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neoplasms 1Neoadjuvant Chemotherapy 1Metastatic Pancreatic Adenocarcinoma 1Locally Advanced Rectal Cancer (LARC) 1

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Efficacy and Safety × irinotecan sucrosofate × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡